Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
30.27 USD +0.63% Intraday chart for Supernus Pharmaceuticals, Inc. +3.28% +4.60%
04-08 Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready DJ
04-08 Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Supernus Pharmaceuticals, Inc. Announces Executive Changes
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling
US Consumer group seeks stronger warnings on Botox, similar treatments
Supernus Pharmaceuticals Insider Sold Shares Worth $259,151, According to a Recent SEC Filing
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023
Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device
Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms
Insider Sell: Supernus Pharmaceuticals
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
  5. Other languages